cell line categorization as "sensitive" or "resistant" between CCLE and GDSC data (Fig. 1f, Extended Data Fig. 3 ). This consistency was evident even when using a simple drug sensitivity cut-off (1 μ M) across all the drugs tested (Extended Data Fig. 3) . Thus, both categorization approaches showed higher consistency than reported in the earlier study 7
P erforming in vitro pharmacological sensitivity studies across panels of molecularly characterized cancer cell lines has proved useful in assessing the cellular activity of many compounds, assigning mechanisms of drug action, and determining genetic contexts for distinct cancer vulnerabilities [1] [2] [3] [4] [5] [6] . A recent comparison study 7 of the Cancer Cell Line Encyclopedia (CCLE) 8 and the Genomics of Drug Sensitivity in Cancer (GDSC) 9 reported poor correlations between their pharmacological data, thus questioning the validity of some conclusions. These observations raised important questions for the field about how best to perform comparisons of large-scale data sets, evaluate the robustness of such studies, and interpret their analytical outputs.
To address these questions, we performed a systematic comparison of the CCLE and GDSC pharmacological data and drug sensitivity predictors. Our results show that when biologically-grounded analytical considerations are incorporated, pharmacological data from the CCLE and GDSC studies exhibit reasonable consistency. Most importantly, these analyses demonstrate that data from either study yields similar predictors of drug response.
Comparison of cell line pharmacological data sets
To evaluate the consistency of the pharmacological data from the two studies, we first performed a comparative analysis of CCLE and GDSC drug screening metrics. For this analysis, we used both the 50% inhibitory concentration (IC 50 ) and the area under the curve (AUC; also referred to as activity area in CCLE when considering 1− AUC). Importantly, IC 50 values were capped at the maximum tested drug concentrations to ensure that they could be properly compared between both data sets (Supplementary Data 1). Also, a fixed axis scale was applied across all compounds to facilitate visualization (Extended Data Fig. 1 ). Of note, while 471 cell lines are present in both CCLE and GDSC collections and have associated genomic data, only a subset of those have overlapping drug screening data: a range of 82-256 cell lines per compound (median = 94 cell lines; mean = 157; Fig. 1a and Supplementary Data 1).
Our analytical approach was designed to account for the fact that many pharmacological profiles exhibit highly discontinuous distributions across cancer cell line collections. Whereas a subset of individual lines may show marked pharmacological sensitivity, the remaining lines-often the vast majority of cell lines in the collection-may be relatively insensitive to a given drug. Such 'outlier' distributions are expected, as they are typically observed for drugs that target specific oncogenic dependencies. Given the relative paucity of sensitive outliers, appropriate pharmacological assessments require multiple drugsensitive cell lines for each compound and the ability to discern this relevant signal against a background dominated by the insensitive majority. Additionally, small data sets containing exclusively insensitive lines are not expected to display significant correlations given the inherent noise in their drug response data.
In cases where direct GDSC-CCLE comparisons were possible, nearly all compounds (13/15) exhibited AUC and IC 50 distributions dominated by drug-insensitive lines, with a much smaller number of drugsensitive outliers. The complete distributions of all CCLE and GDSC AUC values are illustrated for each compound by '"violin plots", while overlapping lines are displayed as a scatter plot (representative examples are shown in Fig. 1 , and all plots in Extended Data Fig. 1) ; results for IC 50 values are similar (Extended Data Fig. 1 ). Ten compounds (saracatinib (also known as AZD0530), erlotinib, lapatinib, nilotinib, crizotinib, nutlin-3, PD0332991, PHA665752, PLX4720 and sorafenib) exhibited AUC values skewed heavily towards the drug-insensitive end of the spectrum. Notably, several targeted anticancer drugs had very few (if any) drug-sensitive lines in the overlapping set (for example, 2 for crizotinib, 3 for nilotinib, 2 for TAE684, and zero for erlotinib or sorafenib; Fig. 1b, c and Extended Data Fig. 1 ). This relative paucity of drug-sensitive cell lines in the overlapping set constrained the level of correlation achievable.
Nevertheless, a correlation analysis that accounted for the imbalance between the number of sensitive and insensitive cell lines, and for differences in the original analytical methodologies, yielded good consistency in most cases (see Extended Data Fig. 2 , comparing Spearman's and Pearson's correlations properties in this context, and Supplementary Discussion). When using the Pearson correlation coefficient instead of Spearman's, as well as consistently capped drug sensitivity metrics, correlation values were clearly improved for most drugs compared to the earlier comparison study 7 (Fig. 1d , e, Methods and Supplementary Discussion). We noted that some correlation values remained poor, either owing to differences in cell line biology, in actual pharmacological measurements (for example, nutlin-3, paclitaxel and PHA665752), or because sensitive lines were only present in one of the cell line collections (for example, erlotinib and sorafenib), preventing any meaningful comparison (Fig. 1c) .
To complement this correlation analysis, we used a waterfall plot-based assessment (Extended Data Fig. 3 shows a schematic of the workflow and further details are provided in the Supplementary Discussion). This analysis confirmed that on average, 94% of cell lines for the 13 relevant compounds (CCLE mean = 94%, range = 77-100%; GDSC mean = 96%, range = 86-100%; Supplementary Data 2) clustered within a druginsensitive range (for example, IC 50 values of >1 μ M for most compounds). These waterfall analyses also showed a high consistency of (see Supplementary Discussion). These results indicated that the CCLE and GDSC cell line pharmacological screening data are best suited for modelling studies that distinguish rare, drug-sensitive lines from "all others" (for example, from drug-insensitive lines that are not expected to contribute meaningful molecular or genetic information).
Comparison of drug sensitivity predictors
Next, we considered the extent to which the CCLE and GDSC cell line collections illuminated common genetic or molecular underpinnings of anticancer drug efficacy. Such insights provide one of the most relevant measures for concordance and utility of pharmacological screening data, given that these efforts are designed to identify such predictors of drug response. First, we determined whether molecular correlates of drug response were aligned between the two data sets. Here we performed an analysis of variance (ANOVA) using the overlapping lines across the CCLE and GDSC. We considered two models where the predicted variables were IC 50 values or activity area (that is, 1− AUC) scores, respectively. In both models we considered the tissue of origin as a covariate and the mutational status of 71 oncogenes as independent variables.
ANOVA identified known genetic biomarkers of sensitivity or resistance as top molecular correlates in at least one data set for 13/15 compounds, and in both data sets for 8/15 compounds (Fig. 2a , Extended Data Fig. 4, Supplementary Data 3) . Genetic correlates in both data sets included NRAS mutation and sensitivity to MEK inhibitor PD0325901, BRAF mutations and sensitivity to BRAF inhibitor PLX4720, the BCR-ABL1 fusion gene and sensitivity to multiple ABL1 inhibitors (nilotinib, AZD0530) and sensitivity of ERBB2-amplified cells to ERBB2 inhibitor lapatinib (identified when using IC 50 values; Extended Data  Fig. 4) . Additionally, drug resistance associations such as TP53 mutations and resistance to nutlin-3 were recovered consistently using activity area scores. When ANOVA was fitted to activity area, 14 drugs for the GDSC and 15 for the CCLE also showed lineage-specific response associations that were consistent across data sets (post-hoc Welch t-test; Extended Data Fig. 5 and Supplementary Data 4 and 7). 7 (x axis) and the present study (y axis) for sensitivity/resistance calling using a waterfall plot analysis.
In a more comprehensive assessment of the consistency of genomic predictors, we applied a multivariate analysis across 21,013 genomic features encompassing expression, copy number changes and mutations 8, 9 . Elastic net regression was performed using either the full data set available for each study or only the overlapping data sets. This analysis yielded robust response predictors, and the overlap of predictors was highly significant (χ 2 P < 10 −8 ; Extended Data Fig. 6 , Supplementary Data 5). Here again, known genomic predictors of drug response emerged as top molecular correlates in at least one data set for 13/15 compounds; 10/15 compounds showed such correlates in both data sets (Supplementary Data 5), as reported previously by CCLE and GDSC using their individual data sets 8, 9 . For some drugs, extending elastic net regression analyses of IC 50 values beyond just the overlapping cell lines identified additional genetic predictors of clinical activity. MDM2 expression and TP53 mutations in the case of nutlin-3 sensitivity provide one example. Moreover, among 4,957 drug-gene associations found using elastic net modelling on each data set, we only observed one divergent result (0.02%) between the two studies.
To further explore how the two data sets might be leveraged to identify genomic predictors of drug sensitivity, we performed a two-step analysis where predictors were identified using one data set and their effects were analysed in the other data set. Here, we used elastic net regression to identify the genomic features and ridge regression to compare their effect across the data sets ( Fig. 2b and Supplementary Discussion). Additionally, we performed this discovery step either on the overlapping cell lines or on all lines available in the respective studies.
We again observed a high consistency of predictive genomic features identified across the CCLE and GDSC studies, even for drugs where few overlapping cell lines were available. Indeed, > 80% of these features identified with concordant directionality in both studies (Fig. 2c, d , Extended Data Figs 7-9 and Supplementary Data 6, features with same sign). In some instances, no predictors could be identified by the initial elastic net regression. This was often attributable at least in part to small numbers of drug-sensitive cell lines, as noted above (Extended Data Fig. 10 ). On the other hand, some drugs that exhibited low correlations based on the AUC or IC 50 analyses nonetheless enabled identification of consistent predictors (for example, nutlin-3; Fig. 2d ).
Together, these results indicate that the CCLE and GDSC pharmacological data sets exhibit reasonable predictive power both separately and when taken as a whole. Many of the resulting drug response predictions are well validated by prior knowledge and clinical evidence. In this regard, not only do the two sets of drug screening data exhibit broad convergence-they also provide examples of consilience: a phenomenon in which independent lines of experimental evidence, each with their own inherent limitations, arrive at fundamental scientific agreement.
Discussion
In summary, when analytical and biological considerations are incorporated that reflect the nature of oncogenic dependency, pharmacological data from the CCLE and GDSC studies exhibit reasonable consistency. Based on positive Pearson correlations (R > 0.5), we observed agreement across the CCLE and GDSC data sets for the majority (67%) of evaluable compounds (two drugs with clear positive regression slopes showed R values just under 0.5 for the IC 50 values; Extended Data Fig. 1 ). We acknowledge that the consistency is not perfect: numerous biological and methodological components (for example, numbers of cell lines seeded per well, drug concentration range examined, number of cell doublings achieved, cell viability assays, analytical tools to calculate sensitivity values, and so on) undoubtedly reduced the statistical correlation of the overlapping pharmacological data. Further standardization of such methodologies will certainly improve correlation metrics, and we welcome efforts in this direction. Nonetheless, both the CCLE and GDSC groups used standard methods for testing drug responses in cell lines, and this analysis confirmed that the consistency of their results seems reasonable in light of the aforementioned methodological differences.
The identification of molecular predictors of drug response remains a major challenge for cancer precision medicine. Accordingly, large-scale (82) AZD6244 (218) Crizotinib (84) Erlotinib (75) Lapatinib (78) Nilotinib (185) Nutlin-3 (233) PD0325901 (232) PD0332991 (182) PLX4720 (234) TAE684 (84) Features with same sign in CCLE ridge (%)
Features with same sign in GDSC ridge (%) screening of clinically relevant compounds across molecularly annotated cancer cell line collections is likely to remain a crucial preclinical source for hypothesis generation. The CCLE 8 and GDSC 9 data sets, the two biggest public collections of genomic and pharmacological cell line data, have produced largely concordant results thus far, although rigorous comparisons should continue to be performed as these data sets evolve. Although neither data set is perfect on its own, they have both shown clear utility for predictive modelling studies and, in several cases, convergence onto known biological principles. Principled analytical frameworks (together with improved standardization) may conceivably illuminate additional areas of consilience through comparative studies of other functional screens (for example, RNA interference, CRISPR genome editing, phospho-proteomics, etc.) in the future. In all such instances, knowledge of the underlying biology should guide the implementation of those analytical and statistical methods best suited for comparative studies and, more generally, the extraction of meaning from large-scale screening data in cancer and other disease models.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Power analysis.
To estimate and compare the statistical power of Spearman and Pearson correlation tests, we ran the following simulation using synthetically generated drug data: starting with 1,000 cell lines with α percent of them drug-sensitive (α = 2%, 5%, 10%, and 50%), we randomly selected a subset of N samples (N between 3 and 500) and calculated the Spearman and Pearson correlations between the two data sets over the N overlapping samples. We also calculated the statistical power for each test, by calculating the percentage of the time the corresponding P ≤ 0.05. In this analysis, we assumed that in both data sets, the drug response data has a Gaussian distribution with N(0,σ 2 ) for insensitive and N(4σ,σ 2 ) for sensitive cell lines. ANOVA. The ANOVA was performed on the data set corresponding to the overlapping set of cell lines and using the genomic and tissue annotations and methods described in Garnett et al.
9
. Specifically, a vector of length n consisting of AUC (respectively IC 50 ) scores for n cell lines was constructed for each drug. A linear (no interaction terms) ANOVA model was then fitted to these scores with factors including the cell line tissue type and the mutation status of 71 cancer genes, in turn. Significance and effect size (computed by using the Cohen's D) were obtained for each of the genedrug pairs. This effect size measures the relative difference in the average AUC (respectively IC 50 ) from the wild-type to mutant group compared to the AUC (respectively IC 50 ) pooled standard deviation of the two groups. P values were subsequently corrected for multiple hypothesis testing with the Benjamini-Hochberg method and a threshold of 20% FDR was used to identify significant associations. Subsequently, systematic unpaired Welch's t-tests were performed to identify tissue/drug-response associations for the drugs showing response differences across different tissues, according the ANOVA models.
Elastic net (EN).
Since the IC 50 is not reported in CCLE when it exceeds the tested range of 8 μ M, we used the activity area for the regression as in the original CCLE publication. We also used the values considered to be the best in the original GDSC study: the interpolated log(IC 50 ) values. This setting might not be the most comparable to the CCLE study, but it was felt to be more powerful from the standpoint of detecting bona fide associations. In order to compare features between the two studies, we used the same genomic data set (CCLE).
For the GDSC regression we matched the CCLE genomic features cell line names to the GDSC cell line names. From the CCLE genomic features we used 18,900 gene expressions, 1,643 genes probed for mutation (excluding 5′ UTR, introns, 3′ UTR, silent mutations), copy numbers for 446 genes (the Cosmic cancer census genes) and 24 tissues. Elastic net regression was performed as described in Garnett et al. 9 , using 100 independent runs. For each iteration, the data are cross-validated with a random tenfold partition of the samples. Elastic net performs feature selection: unselected features have zero coefficients. Frequency is the proportion of models out of the 100 runs where the coefficient is non-zero. Note that when we restricted the drug responses to overlapping cell lines/drugs between the two studies, only 12/15 drugs had any features, both in the CCLE regression and the GDSC regression. Contingency tables of sensitive and resistant features in both studies are in Extended Data Fig. 6b . To assess significance of the overlap between the results, χ 2 statistics were computed on the two-by-two contingency tables of sensitive and resistant features (Extended Data Fig. 6a) . Ridge regression. After performing elastic net regression as described above, the genomic features identified were applied to a ridge regression using the same responses as in the elastic net, that is, the IC 50 values for GDSC (including extrapolated values) and activity area for CCLE. Ridge regression was performed using all features selected by elastic net (Fig. 2b-d and Extended Data Fig. 7) . In all plots the axes represent the weights attributed in the ridge regressions that were multiplied by the standard deviation of the features as in Garnett et al. 9 , and then standardized per drug. The data points are shaded according to their elastic net frequency.
Several measures of consilience of drug-feature associations between the two studies were then computed (Extended Data Fig. 8) . In order to gain statistical power, we also performed elastic net regression using all cell lines available in each study separately, and compared the results (Extended Data Fig. 8, second row) . Consilience was computed using agreement proportion (that is, the proportion of drug-feature associations with the same sign between the two studies), cosine correlation and Spearman correlation. Cosine correlation conserves the sign of the compared values before scalar product and is therefore a better measure of consilience when only a few features are available for comparison (see for instance nutlin-3 in CCLE panels, Extended Data Fig. 8) .
Waterfall method for categorization of cell lines. Our implementation of the waterfall method follows the steps introduced in Barretina et al. 8 and described by Haibe-Kains et al.
7
, with one exception: we only distinguished between sensitive and resistant cell lines. Hence, we removed the intermediate group altogether for simplicity, which allowed for a more straightforward comparison of the two studies. The specific approach we used is outlined as follows.
The drug sensitivity measurements were extracted (IC 50 values for all cell lines measured in the GDSC and CCLE studies). This is a major difference to the Haibe-Kains et al. analysis 7 , as that analysis only considered the cell-lines in common between the studies when generating response distribution curves. Increasing log 10 (IC 50 ) values were then sorted to generate a waterfall distribution. If the waterfall distribution is nonlinear (Pearson correlation coefficient to the linear fit ≤0.95), the inflection point of the log 10 (IC 50 ) curve was estimated as the point on the curve with the maximal distance to a line drawn between the start and end points of the distribution. If the waterfall distribution appears linear (Pearson correlation coefficient >0.95), the median log 10 (IC 50 ) was used instead. Cell lines with log 10 (IC 50 ) below this inflection point were classified as sensitive, whereas the rest were deemed resistant (see the estimated inflection points in Supplementary Data 2).
Using this approach, we generated drug sensitivity calls for all cell lines within the GDSC and CCLE studies and employed the Cohen's Kappa statistical analysis of agreement. Drug sensitivity analysis scenarios. Using the waterfall method, we estimated inflexion points (which ultimately differentiate between sensitive and resistant cell-lines), on all available/measured cell-lines (for a given drug), in order to have a more complete drug response curve and as a result, better sensitivity agreements (blue bars in Extended Data Fig. 3) .
Without the waterfall method, we used a fixed threshold of 1 μ M for each drug, in order to distinguish between sensitive and resistant cell-lines. This was much simpler and faster than the previous approach, while generating similar results (green bars in Extended Data Fig. 3) . Code availability. Most of the analyses performed in this paper were implemented in R. The R package containing the source codes can be accessed at http://www. broadinstitute.org/ccle/Rpackage. (20 out of 1,000) data points using synthetic data. The Spearman statistic completely fails to detect such a signal which is typical for selective cancer therapeutics. b, c, Expected Spearman and Pearson correlation coefficients between the two data sets assuming different percentages of drug-sensitive cell lines (α = 2%, 5%, 10% and 50%) and different number of overlapping cell lines. The error bars depict ± one standard deviation. d, e, Estimated statistical power for Spearman and Pearson correlation tests using a P value cutoff of 0.05 for rejecting the null hypothesis. This analysis was done using synthetic data as described in the Methods. Extended Data Figure 5 | Consistency of drug sensitivity/tissue-oforigin associations between the CCLE and GDSC data sets. Each point is a tested association between drug response and a given cell line's tissue of origin. Positions of the points on the two axes correspond to 'signed log q-values' of the corresponding tests for the two data sets, respectively. Point labels indicate drug names and targets (in italics) and tested tissue (among round brackets). The sign indicates the effect of the marker (neg = increased sensitivity and pos = increased resistance) and the magnitude indicates the log P value of the corresponding t-test, after correcting for multiple hypothesis testing. Fisher's exact test P values for independence of columns and rows of the contingency table determined by sign and significance of the associations are also reported (over all the tests and for significant associations only, respectively). 
